SATO VICKI L 4

What Happened
Vicki L. Sato, a director of Vir Biotechnology, sold 22,000 shares in an open-market disposition on May 1, 2026. The sales were reported at a weighted average price of $10.05 (prices ranged $9.94–$10.23), for total gross proceeds of approximately $221,025. This was a sale (code S), which is typically a routine disposition rather than an indication of company outlook.

Key Details

• Transaction date: 2026-05-01 (reported on Form 4 filed 2026-05-04).
• Transaction type: Open-market sale (Code S).
• Shares sold: 22,000.
• Price: Weighted average $10.05; individual sale prices ranged from $9.94 to $10.23.
• Proceeds: Approximately $221,025 (gross).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes:
  • F1: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2025.
  • F2: Reported price is a weighted average; the reporting person will provide a breakdown of shares sold at each price in the stated range upon request.
• Timeliness: Form 4 filed May 4, 2026; the filing does not indicate a late filing flag in the provided data.

Context
Trades executed under a 10b5-1 plan are pre-arranged and are commonly used by insiders to sell shares on a preset schedule (e.g., for diversification or tax planning). Such sales are routine and do not necessarily reflect the insider’s current view of the company’s prospects. For investors tracking insider activity, purchases generally carry more direct informational weight than routine sales.